|Year : 2017 | Volume
| Issue : 4 | Page : 158-163
Cardiac manifestations of Familial Mediterranean fever
Ahmad Alsarah1, Osama Alsara2, Heather S Laird-Fick1
1 Department of Internal Medicine, Michigan State University, East Lansing, MI, USA
2 Department of Cardiovascular Diseases, University of Florida, Gainesville, FL, USA
|Date of Web Publication||11-Oct-2017|
Department of Cardiovascular Diseases, University of Florida, 1600 SW Archer Road, RM M-430, Gainesville, FL 32610
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Familial Mediterranean fever (FMF) is autoinflammatory disorder characterized by sporadic attacks of fever, peritonitis, pleuritis, and arthritis. It is mainly seen in patients from Mediterranean origins, but it is now reported more frequently in Europe and North America due to immigration. To analyze the data on the cardiovascular manifestations in FMF patients, we searched PubMed using the terms “Familial Mediterranean Fever” or “FMF” in combination with other key words including “cardiovascular diseases” “pericardial diseases” “atherosclerosis” “coronary artery diseases” “cardiomyopathy” “pulmonary hypertension” or “valvular diseases.” suggested several mechanisms to explain the cardiac involvements in FMF including the ongoing inflammation and the amyloid deposits in the heart and vessels' walls at the advanced stages of FMF. The course of these manifestations varies widely, but it can associate with poor prognosis in some cases such as with pulmonary hypertension. Interestingly, Colchicine, which is the cornerstone therapy of FMF, plays a vital role in treating and preventing some of these disorders. In this article, In this article, we will discuss the incidence, pathophysiology, and prognosis of the various cardiac manifestations affecting FMF patients.
Keywords: Atherosclerosis, cardiomyopathy, coronary artery disease, familial mediterranean fever, pericarditis
|How to cite this article:|
Alsarah A, Alsara O, Laird-Fick HS. Cardiac manifestations of Familial Mediterranean fever. Avicenna J Med 2017;7:158-63
| Introduction|| |
Familial Mediterranean fever More Details (FMF) is autoinflammatory disease characterized by periodic episodes of fever, peritonitis, pleuritis, and arthritis. It is mostly inherited as autosomal recessive disorder among people from specific ethnicities such as Turks, Arabs, Armenians, and nonAshkenazi Jews. In those patients, MEFV gene which is responsible for the production of Pyrin protein, an important regulator of inflammation and immune response, is mutated. Patients with defective Pyrin tend to develop an inappropriate inflammatory response leading to the typical symptoms of FMF. While the diagnosis of FMF can be highly suspected depending on the clinical picture, family history, ethnicity, and response to colchicine therapy, the definite diagnosis of this disorder can only be confirmed by genetic analysis.
Several organs and systems affected by FMF, including the renal, gastrointestinal, and musculoskeletal systems. While cardiovascular involvements are less commonly reported, it is important to recognize those complications as some of them are associated with an increased morbidities and/or mortality. In this article, we will review the available literature and discuss the various cardiac manifestations of FMF, their incidence, pathophysiology, and prognosis.
| Methods|| |
A comprehensive review of the literature is conducted to analyze the data on the cardiovascular manifestations in FMF patients. Using PubMed as the database, the literature search was carried out for English articles published between 1960 and 2016. We used in our search the terms “Familial Mediterranean Fever” or “FMF” in combination with other key words including “cardiovascular diseases,” “pericardial diseases,” “atherosclerosis,” “coronary artery diseases,” “cardiomyopathy,” “pulmonary hypertension,” or “valvular diseases.” We selected the papers of most relevance to this review for discussion including observational studies, case series, and case reports. We excluded the articles that were duplicates. We also performed a manual search of the references of the selected articles for any relevant articles that we might have missed.
| Pericardial Diseases|| |
Several studies and case reports have described the pericardial involvement in FMF patients including acute and recurrent pericarditis, constrictive pericarditis, pericardial effusion, and tamponade. These articles reviewed and summarized in [Table 1].
|Table 1: Pericardial diseases in patients with Familial Mediterranean fever|
Click here to view
Pericarditis is commonly seen with FMF, presenting usually as chest pain that lasts for about 4 days and then resolves spontaneously without further complications. Yet, massive pericardial effusions and cardiac tamponade have been reported requiring pericardiocentesis.,,,
Although Sohar et al. did not find any case of pericarditis when they retrospectively reviewed the symptoms of 470 FMF patients, many studies have found that the incidence of pericarditis in FMF patients is higher than the general population. The prevalence of pericarditis varied from 0.7%–1.4% in some retrospective studies, to 3.6% in one prospective study that used echocardiogram for diagnosis. Using M-mode echocardiography, Dabestani et al. reported pericardial changes (effusion or thickening) in about quarter of their group. In a recent study, Kilic et al. diagnosed pericarditis in about 11% of children with FMF presenting with chest pain and showed that pericarditis was especially seen in those with M694V and E148Q mutations.
While pericarditis typically presents simultaneously with other FMF symptoms, it has been reported as the only manifestation of the attack.,,,,, In those cases, recurrent pericarditis which are refractory to the typical treatments raised the suspicion of FMF requiring further genetic studies to confirm the diagnosis.
Constrictive pericarditis, a rare pericardial complication, has also been diagnosed in FMF patients using chest X-ray and echocardiogram., Although pericardiectomy is the main treatment of this disorder, conservative management has been used by Gökçe et al., who showed a complete disappearance of constrictive pericarditis after 6 months of regular colchicine therapy.
| Atherosclerosis and Coronary Artery Diseases|| |
Even though FMF patients are symptoms free between the attacks, C-reactive protein was detected in the attack free periods indicating a continuous subclinical inflammation between the clinical episodes. Since systemic inflammation stimulates the development and progression of atherosclerosis, many researchers are now questioning whether FMF patients are at a higher risk of atherosclerosis and coronary artery diseases (CAD) than other patients.
While atherosclerotic plaques are rarely seen in FMF patients,,,, intima media of the carotid and femoral arteries were found to be thick in various studies, suggesting of preclinical atherosclerosis.,, Furthermore, this thickness associated with endothelial dysfunction and correlated with increased in inflammatory markers. Two studies though failed to show any significant difference in intima-media thickening between FMF patients and other patients., This conflict between the studies may suggest that FMF patients are at a slightly higher risk of developing subclinical atherosclerosis and that its progression is not aggressive enough to result in a significant plaque. In addition, colchicine therapy with its antiatherosclerotic characteristics may be the slowing factor of this process, but we still need more trials to clarify this point [Table 2]. Reviews the studies of intima-media thickness in FMF patients.
|Table 2: Review of studies that evaluated Intima-Media Thickening in patients with Familial Mediterranean fever|
Click here to view
The relationship between FMF and CAD has been suggested in two genetic studies. Grimaldi et al. evaluated the prevalence of three of the mutations causing FMF in a group of Sicilian patients with acute myocardial infarction (AMI). The authors found that M694V mutation is over-represented in AMI patients and it predicted a significant risk to develop AMI even after adjustment for other cardiac risk factors. Similarly, Kisacik et al. studied the prevalence of MEFV mutations in 197 CAD patients (91 with early CAD and 106 patients with typical CAD) and compared them to 119 healthy controls. In this study, MEFV mutations in patients with early CAD were significantly higher compared to both older CAD patients and healthy controls. Yet, only three cases of acute coronary syndrome have been reported in FMF patients; all of them were young, and at least, two of them had fatal myocardial infarction. The first case was reported by Puricel et al. when they reviewed the data on patients suffering acute coronary syndrome at age <30 years old. Uyarel et al. described another case of a 22-year-old FMF patient who deceased due to myocardial infarction after stopping colchicine therapy. The third case was reported by Serrano et al. of a 29-year-old female with a history of FMF and amyloidosis who experienced a fatal AMI due to coronary vasculitis. CAD in FMF patients seems to be a consequence of either the augmented atherosclerosis or amyloid depositions in the vascular walls as was demonstrated in autopsy analysis. Since colchicine suppresses the progression of these two factors, it may play an important protective role against CAD in those patients. This can explain the lower frequency of ischemic heart disease in colchicine-treated FMF patients compared to the general population.
| Cardiomyopathy|| |
Cardiac amyloidosis is a late complication reported in about 13% of FMF patients. It presents mainly as progressive cardiomyopathy due to amyloid deposit in the myocardium. Both sides of the heart can be effected, resulting in either systolic or diastolic dysfunction., Nir-Paz et al. reported a very interesting case of a 50-year-old woman who had several admissions of fever, cough, and fatigue presented with the left heart failure and left bundle branch block. An echocardiography revealed a mildly dilated left ventricle with mild-to-moderate left ventricular systolic dysfunction. A myocardial biopsy revealed amyloid deposition around myocytes, and a genetic test showed M694V mutation confirming the diagnosis of FMF. Interestingly, early subclinical changes in myocardial tissues can now be detected by strain and strain rate echocardiography techniques even in asymptomatic FMF patients who used to have normal heart function by the conventional echocardiography. Although the prognosis of amyloidosis induced cardiomyopathy in FMF patients is not well defined, at least one case of mortality has been reported in this population due to advanced heart failure.
| Pulmonary Hypertension|| |
Pulmonary hypertension should be suspected in patients at advanced stages of FMF presenting with shortness of breath, fatigue, recurrent fever, and symptoms of the right ventricular failure. Although most researchers believe pulmonary hypertension in FMF is a result of pulmonary amyloidosis, Sargsyan and Narimanyan have diagnosed elevated pulmonary pressure in 6% of FMF patients without any evidence of amyloidosis. In general, those patients seem to have very poor prognosis. Johnson and Lie reported a case of 48-year-old FMF patient who was diagnosed with pulmonary hypertension and then developed hypoxia, hypotension, and terminal cardiac arrhythmias that were the immediate cause of her death. Likewise, in a retrospective study at the Mayo Clinic of patients with pulmonary hypertension due to amyloidosis, the authors reported a case of FMF patient who died 61 days after her diagnosis with pulmonary hypertension as a result of advanced heart failure.
| Valvular Diseases|| |
In a cohort study of a group of children who were diagnosed with FMF, Salah et al. showed that valvular diseases affect about half of the patients in rates vary from 21.8% for aortic valve, 16% for mitral valve, and 11% for the pulmonary valve. Different degrees of tricuspid regurgitation were reported as well in another study. These findings are attributed to amyloid deposition on heart valves during the course of FMF or they may be related to rheumatic heart disease which is believed to affect FMF patients more than others.
| Colchicine and Cardiovascular Diseases in Familial Mediterranean Fever|| |
Colchicine has been the core treatment of FMF being so effective not only in suppressing the acute inflammatory attacks but also reducing the recurrence rate and subsequently preventing the development of amyloidosis. These benefits are believed to be related to its ability to suppress some of the functions of neutrophils, T-cells, and endothelial cells. At the same time, colchicine inhibits vascular hyperplasia and fibrosis and hence plays an important role in preventing atherosclerosis and myocardial infarction. The use of colchicine in cardiovascular medicine has been mainly restricted to the management of acute and recurrent pericarditis in patients who failed to respond to conventional treatment. Despite the limited articles discussing the effect of colchicine on other cardiac manifestations of FMF, some data suggest a cardioprotective role. For instance, Sari et al. showed that the regular treatment with colchicine may prevent atherosclerosis and endothelial dysfunction in FMF patients. Similarly, Langevitz et al. found that the frequency of ischemic heart disease was lower in colchicine-treated FMF patients compared to the general population.
| Conclusion|| |
Various cardiovascular manifestations have been described in patients with FMF, including pericarditis, valvular diseases, CAD, cardiomyopathies, subclinical atherosclerosis, and pulmonary hypertension. Two main mechanisms, at least, are suggested: The ongoing inflammation and the amyloid deposition in the heart and vessels. By reducing these factors, colchicine, the cornerstone therapy of FMF, has been shown as an important agent in treating and preventing some of these disorders. The prognosis of cardiac complications of FMF is not well studied. However, mortality has been particularly reported in patients developing pulmonary hypertension, AMI, and cardiomyopathy. While this article presented the available data on the prevalence, pathophysiology, and prognosis of cardiac diseases in FMF patients, more studies with larger number of patients are needed to explore the relationship between cardiovascular diseases and FMF to provide better understanding of these disorders.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Onen F. Familial Mediterranean fever. Rheumatol Int 2006;26:489-96.
Rigante D, Cantarini L, Imazio M, Lucherini OM, Sacco E, Galeazzi M, et al.
Autoinflammatory diseases and cardiovascular manifestations. Ann Med 2011;43:341-6.
Eliakim M, Ehrenfeld EN. Electrocardiographic changes in recurrent polyserositis (“periodic disease”). Am J Cardiol 1961;7:517-20.
Zemer D, Cabili S, Revach M, Shahin N. Constrictive pericarditis in familial Mediterranean fever. Isr J Med Sci 1977;13:55-8.
Dabestani A, Noble LM, Child JS, Krivokapich J, Schwabe AD. Pericardial disease in familial Mediterranean fever: An echocardiographic study. Chest 1982;81:592-5.
Zimand S, Tauber T, Hegesch T, Aladjem M. Familial Mediterranean fever presenting with massive cardiac tamponade. Clin Exp Rheumatol 1994;12:67-9.
Tauber T, Zimand S, Kotzer E. Recurrent pericarditis in familial Mediterranean feve]. Harefuah 1995;128:611-2, 672.
Kees S, Langevitz P, Zemer D, Padeh S, Pras M, Livneh A, et al.
Attacks of pericarditis as a manifestation of Familial Mediterranean fever (FMF). QJM 1997;90:643-7.
Tutar HE, Imamoglu A, Kendirli T, Akar E, Atalay S, Akar N, et al.
Isolated recurrent pericarditis in a patient with familial Mediterranean fever. Eur J Pediatr 2001;160:264-5.
Tutar E, Yalçinkaya F, Ozkaya N, Ekim M, Atalay S. Incidence of pericardial effusion during attacks of familial Mediterranean fever. Heart 2003;89:1257-8.
Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F, et al
. Familial Mediterranean fever (FMF) in Turkey: Results of a nationwide multicenter study. Medicine (Baltimore) 2005;84:1-1.
Ishak GE, Khoury NJ, Birjawi GA, El-Zein YR, Naffaa LN, Haddad MC, et al.
Imaging findings of familial Mediterranean fever. Clin Imaging 2006;30:153-9.
Okutur K, Seber S, Oztekin E, Bes C, Borlu F. Recurrent pericarditis as the initial manifestation of familial Mediterranean fever. Med Sci Monit 2008;14:CS139-41.
Gökçe I, Gökçe S, Kılıç A, Bozlar U, Kocaoğlu M, Ongürü O, et al.
Familial Mediteranean fever with protein-losing enteropathy due to constrictive pericarditis. World J Pediatr 2011;7:365-7.
Yoshioka K, Furumitsu Y, Sano T, Miyamoto T, Agematsu K. Acute pericarditis as the first manifestation of familial Mediterranean fever: A possible relationship with idiopathic recurrent pericarditis. Intern Med 2014;53:1659-63.
Sánchez Ferrer F, Martinez Villar M, Fernández Bernal A, Martín de Lara I, Paya Elorza I. Cardiac tamponade as first manifestation in Mediterranean fever with autosomal dominant form. An Pediatr (Barc) 2015;82:e82-5.
Kilic A, Varkal MA, Durmus MS, Yildiz I, Yıldırım ZN, Turunc G, et al.
Relationship between clinical findings and genetic mutations in patients with familial Mediterranean fever. Pediatr Rheumatol Online J 2015;13:59.
Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967;43:227-53.
Lachmann HJ, Sengül B, Yavuzşen TU, Booth DR, Booth SE, Bybee A, et al.
Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006;45:746-50.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
Akdogan A, Calguneri M, Yavuz B, Arslan EB, Kalyoncu U, Sahiner L, et al.
Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. J Am Coll Cardiol 2006;48:2351-3.
Ugurlu S, Seyahi E, Cetinkaya F, Ozbakir F, Balci H, Ozdogan H, et al.
Intima-media thickening in patients with familial Mediterranean fever. Rheumatology (Oxford) 2009;48:911-5.
Sari I, Karaoglu O, Can G, Akar S, Gulcu A, Birlik M, et al.
Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever. Clin Rheumatol 2007;26:1467-73.
Ugurlu S, Samet K, Demirel Y, Emire S. Subclinical atherosclerosis and oxidized LDL levels in familial Mediterranean fever. Ann Rheum Dis 2014;71 Suppl 3:707.
Bilginer Y, Ozaltin F, Basaran C, Duzova A, Besbas N, Topaloglu R, et al.
Evaluation of intima media thickness of the common and internal carotid arteries with inflammatory markers in familial Mediterranean fever as possible predictors for atherosclerosis. Rheumatol Int 2008;28:1211-6.
Peru H, Altun B, Doğan M, Kara F, Elmaci AM, Oran B, et al.
The evaluation of carotid intima-media thickness in children with familial Mediterranean fever. Clin Rheumatol 2008;27:689-94.
Ugurlu S, Karaca SN, Demirel Y, Seyahi E. P01-014 – Subclinical atherosclerosis in FMF. Pediatr Rheumatol Online J 2013;11 Suppl 1:A18.
Kucuk A, Uslu AU, Arslan S, Balta S, Ozturk C, Uysal S, et al.
Ischemia-modified albumin and atherosclerosis in patients with familial Mediterranean fever. Angiology 2016;67:456-60.
Grimaldi MP, Candore G, Vasto S, Caruso M, Caimi G, Hoffmann E, et al.
Role of the pyrin M694V (A2080G) allele in acute myocardial infarction and longevity: A study in the Sicilian population. J Leukoc Biol 2006;79:611-5.
Kisacik B, Basar N, Ercan S, Pehlivan Y, Yilmaz S, Simsek I, et al
. Familial Mediterranean fever (FMF) gene mutations (MEFV): Are they a risk factor for coronary artery disease? Ann Rheum Dis 2013;71:637.
Puricel S, Lehner C, Oberhänsli M, Rutz T, Togni M, Stadelmann M, et al.
Acute coronary syndrome in patients younger than 30 years – Aetiologies, baseline characteristics and long-term clinical outcome. Swiss Med Wkly 2013;143:w13816.
Uyarel H, Karabulut A, Okmen E, Cam N. Familial Mediterranean fever and acute anterior myocardial infarction in a young patient. Anadolu Kardiyol Derg 2006;6:272-4.
Serrano R, Martínez MA, Andrés A, Morales JM, Samartin R. Familial Mediterranean fever and acute myocardial infarction secondary to coronary vasculitis. Histopathology 1998;33:163-7.
Ambartsymian SV. Myocardial infarction in patients with familial Mediterranean fever and cardiac lesions. Georgian Med News 2012;(204):62-6.
Langevitz P, Livneh A, Neumann L, Buskila D, Shemer J, Amolsky D, et al.
Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J 2001;3:9-12.
Sargsyan A, Narimanyan M. Pulmonary hypertension in familial Mediterranean fever: Consequence or coincidence? Pediatr Rheumatol Online J 2015;13 Suppl 1:O41.
Sari I, Arican O, Can G, Akdeniz B, Akar S, Birlik M, et al.
Assessment of aortic stiffness and ventricular functions in familial Mediterranean fever. Anadolu Kardiyol Derg 2008;8:271-8.
Baysal T, Peru H, Oran B, Sahin TK, Koksal Y, Karaaslan S, et al.
Left ventricular diastolic function evaluated with tissue Doppler imaging in children with familial Mediterranean fever. Clin Rheumatol 2009;28:23-8.
Nir-Paz R, Ben-Chetrit E, Pikarsky E, Hassin D, Hasin Y, Chajek-Shaul T, et al.
Unusual presentation of familial Mediterranean fever: Role of genetic diagnosis. Ann Rheum Dis 2000;59:836-8.
Ceylan Ö, Özgür S, Örün UA, Doğan V, Yılmaz O, Keskin M, et al.
Assessment of left ventricular functions with tissue Doppler, strain, and strain rate echocardiography in patients with familial Mediterranean fever. Anatol J Cardiol 2015;15:663-8.
Yildiz A, Akkaya V, Kiliçaslan I, Türkmen A, Görçin B, Atilgan D, et al
. Cardiac and intestinal amyloidosis in a renal transplant recipient with familial Mediterranean fever. J Nephrol 2001;14:125-7.
Johnson WJ, Lie JT. Pulmonary hypertension and familial Mediterranean fever: A previously unrecognized association. Mayo Clin Proc 1991;66:919-25.
Dingli D, Utz JP, Gertz MA. Pulmonary hypertension in patients with amyloidosis. Chest 2001;120:1735-8.
Salah S, Hegazy R, Ammar R, Sheba H, Abdelrahman L. MEFV gene mutations and cardiac phenotype in children with familial Mediterranean fever: A cohort study. Pediatr Rheumatol Online J 2014;12:5.
Tekin M, Yalçinkaya F, Tümer N, Cakar N, Koçak H. Familial Mediterranean fever and acute rheumatic fever: A pathogenetic relationship? Clin Rheumatol 1999;18:446-9.
Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD. Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol 2015;11:1781-94.
Cocco G, Chu DC, Pandolfi S. Colchicine in clinical medicine. A guide for internists. Eur J Intern Med 2010;21:503-8.
[Table 1], [Table 2]
|This article has been cited by|
||Optical coherence tomography-angiographic vascular densities in Familial Mediterranean Fever (FMF) Patients with M694V Mutations
| ||Cemal Çavdarli,Büsranur Çavdarli,Pinar Topcu-Yilmaz,Burcu Polat Gültekin |
| ||Ophthalmic Genetics. 2020; : 1 |
|[Pubmed] | [DOI]|
||Donor-Transmitted Melanoma: Is It Still Bothering Us?
| ||Leila Abdullayeva |
| ||Current Treatment Options in Oncology. 2020; 21(5) |
|[Pubmed] | [DOI]|
||Familial Mediterranean Fever Complicated by a Triad of Adrenal Crisis: Amyloid Goiter and Cardiac Amyloidosis
| ||Sadi A. Abukhalaf,Beesan W. Dandis,Tasnim Zatari,Adham M. Amro,Tareq Z. Alzughayyar,Yazan A. Rajabi |
| ||Case Reports in Rheumatology. 2020; 2020: 1 |
|[Pubmed] | [DOI]|
||Familial Mediterranean fever and atherosclerosis in childhood and adolescence
| ||Olga Vampertzi,Kyriaki Papadopoulou-Legbelou,Areti Triantafyllou,Stella Douma,Efimia Papadopoulou-Alataki |
| ||Rheumatology International. 2019; |
|[Pubmed] | [DOI]|
||Colchicine, a microtubule-disassembling drug, in the therapy of cardiovascular diseases
| ||George N. Chaldakov |
| ||Cell Biology International. 2018; |
|[Pubmed] | [DOI]|